

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## RECEIVED

MAY 1 3 2002

Applicant(s): Colin R. Dunstan

TECH CENTER 1600/2900

Serial No.:

09/389,545

Group Art Unit No.: 1642

Filed:

September 3, 1999

Examiner: Helms, L.

For:

Compositions and Methods for the Prevention or

Treatment of Cancer and Bone Loss Associated with

Cancer

Docket No.: A-605

5-14-03

## RESPONSE AND AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Office Action dated November 6, 2001 in which Claims 23-40 were rejected under 35 U.S.C. 112 and 103. Withdrawal of the rejections is requested.

Please amend the application as follows:

In the specification:

At page 45, replace the third paragraph with the following:

Plasmids encoding OPG[1-194]-Fc, OPG[1-201]-Fc, OPG[1-194]-FcΔC, OPG[1-201]-FcΔC, OPG[1-194]-FcΔc, and metFcΔC-OPG[22-194] for use in producing the corresponding OPG fusion polypeptides are constructed generally as described in WO97/23614 and in copending U.S. Serial No. 09/389,545, filed September 3, 1999, both of which are incorporated by reference. The polypeptide sequences are shown in Figures 3-8, respectively.

## **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number:	EL360694166 US	Date of Deposit:	May 6, 2002
above and is addressed to Assistant Co	peing deposited with the United States Postal Service "Exp immissioner for Patents, Box AF, Washington, DC 20231.		o Addressee* service under 326 F.R. 1.10 on the date indicated